The aim of this study was to explore the impact of the degree of inflammation by using C-reactive protein (CRP) and procalcitonin (PCT) serum levels as inflammatory biomarkers on voriconazole exposure in critically ill patients affected by CAPA. The gene discussed is CRP; the disease is episodic ataxia type 2.